NO950483D0 - Vaksine mot hepatitt-A - Google Patents

Vaksine mot hepatitt-A

Info

Publication number
NO950483D0
NO950483D0 NO950483A NO950483A NO950483D0 NO 950483 D0 NO950483 D0 NO 950483D0 NO 950483 A NO950483 A NO 950483A NO 950483 A NO950483 A NO 950483A NO 950483 D0 NO950483 D0 NO 950483D0
Authority
NO
Norway
Prior art keywords
vaccine
hepatitis
Prior art date
Application number
NO950483A
Other languages
English (en)
Other versions
NO950483L (no
Inventor
Robert A Aboud
John G Aunins
Barry C Buckland
Peter A Dephillips
Anna J Hagen
Jr John P Hennessey
Beth Junker
John A Lewis
Cynthia Newell Oliver
Charles J Orella
Robert David Sitrin
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NO950483D0 publication Critical patent/NO950483D0/no
Publication of NO950483L publication Critical patent/NO950483L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/29Hepatitis virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5252Virus inactivated (killed)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/32011Picornaviridae
    • C12N2770/32411Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32434Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/32011Picornaviridae
    • C12N2770/32411Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32451Methods of production or purification of viral material
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/582Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO950483A 1992-08-07 1995-02-09 Vaksine mot hepatitt-A NO950483L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92687392A 1992-08-07 1992-08-07
PCT/US1993/007431 WO1994003589A2 (en) 1992-08-07 1993-08-06 Hepatitis a virus vaccine
CN93117633A CN1099798A (zh) 1992-08-07 1993-08-06 甲型肝炎病毒疫苗

Publications (2)

Publication Number Publication Date
NO950483D0 true NO950483D0 (no) 1995-02-09
NO950483L NO950483L (no) 1995-04-07

Family

ID=36869970

Family Applications (1)

Application Number Title Priority Date Filing Date
NO950483A NO950483L (no) 1992-08-07 1995-02-09 Vaksine mot hepatitt-A

Country Status (16)

Country Link
EP (1) EP0583142A2 (no)
JP (1) JPH0748277A (no)
CN (1) CN1099798A (no)
AU (1) AU4450093A (no)
CA (1) CA2103515A1 (no)
CZ (1) CZ34795A3 (no)
DZ (1) DZ1706A1 (no)
FI (1) FI950567A (no)
HU (1) HUT70982A (no)
MX (1) MX9304803A (no)
NO (1) NO950483L (no)
PL (1) PL307402A1 (no)
SI (1) SI9300421A (no)
SK (1) SK18495A3 (no)
WO (1) WO1994003589A2 (no)
ZA (1) ZA935723B (no)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2096650A1 (en) * 1991-09-18 1993-03-21 Keith E. Langley Hepatitis b vaccine formulation incorporating a bile acid salt
HRP950097A2 (en) * 1994-03-08 1997-06-30 Merck & Co Inc Hepatitis a virus culture process
TW570803B (en) * 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
DE69838340T2 (de) * 1997-10-09 2008-05-21 Wellstat Biologics Corp. Behandlung von neoplasmen mit interferonempfindlichen, klonalen viren
US7780962B2 (en) 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
US20030044384A1 (en) 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
US7470426B1 (en) 1997-10-09 2008-12-30 Wellstat Biologics Corporation Treatment of neoplasms with viruses
HUP0302278A3 (en) 1999-04-15 2011-01-28 Pro Virus Treatment of neoplasms with viruses
KR100421386B1 (ko) * 2001-09-22 2004-03-09 엘지전자 주식회사 초고속용 유도 전동기의 회전자
US6825027B2 (en) 2001-12-10 2004-11-30 Baxter Healthcare S.A. Method of production of purified hepatitis a virus particles and vaccine preparation
BR0309659A (pt) 2002-04-30 2005-02-22 Oncolytics Biotech Inc Método para produzir vìrus de uma cultura de células, composição, e, método para produzir reovìrus infeccioso
GB0304799D0 (en) * 2003-03-03 2003-04-09 Glaxosmithkline Biolog Sa Novel method
WO2005070454A2 (en) * 2004-01-27 2005-08-04 Bharat Biotech International Limited A novel process of hepatitis a vaccine preparation
US7901921B2 (en) * 2004-10-22 2011-03-08 Oncolytics Biotech Inc. Viral purification methods
CN101816786B (zh) * 2010-04-30 2012-09-05 长春生物制品研究所有限责任公司 一种甲型肝炎灭活疫苗及其制备方法
CN102058882B (zh) * 2010-12-28 2012-12-26 深圳康泰生物制品股份有限公司 一种制备甲型肝炎灭活疫苗的方法
CN103013933B (zh) * 2012-12-14 2014-10-22 北京民海生物科技有限公司 人二倍体狂犬病疫苗病毒液的灭活方法
TR201902201T4 (tr) * 2015-07-23 2019-03-21 Grifols Sa İn vi̇tro üreti̇len bi̇r vi̇rüsün saflaştirilmasina yöneli̇k yöntemler ve vi̇rüse yöneli̇k klerens anali̇zi̇.
EP3695849A1 (en) 2019-02-13 2020-08-19 Mediagnost Gesellschaft für Forschung und Herstellung von Diagnostika GmbH Method for extracting hepatitis a virus (hav) antigen from cell culture
CN112202628B (zh) * 2020-09-08 2022-09-02 杭州涂鸦信息技术有限公司 一种WiFi模块串口协议自动化测试系统及方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4296204A (en) * 1978-01-25 1981-10-20 Merck & Co., Inc. Use of motionless mixer as cell culture propagator
US4164566A (en) 1978-08-17 1979-08-14 Merck & Co., Inc. Hepatitis a virus cell culture in vitro
US5021348A (en) 1979-09-04 1991-06-04 Merck & Co., Inc. Attenuated hepatitis A virus
US4415670A (en) 1980-07-07 1983-11-15 Merck & Co., Inc. Motionless mixer as cell culture propagator
US4301249A (en) * 1980-07-23 1981-11-17 Merck & Co., Inc. High titer production of hepatitis A virus
NZ225583A (en) 1987-08-06 1991-07-26 Merck & Co Inc Process for purifying hepatitis a virions (hav)
JPH0751513B2 (ja) * 1988-04-28 1995-06-05 国立予防衛生研究所長 A型肝炎ワクチン
CA2047041A1 (en) * 1990-07-18 1992-01-19 John A. Lewis Process for purification of hepatitis-a virus capsids

Also Published As

Publication number Publication date
WO1994003589A2 (en) 1994-02-17
SK18495A3 (en) 1995-11-08
DZ1706A1 (fr) 2002-02-17
ZA935723B (en) 1995-03-22
EP0583142A2 (en) 1994-02-16
FI950567A0 (fi) 1995-02-09
PL307402A1 (en) 1995-05-15
CZ34795A3 (en) 1996-03-13
SI9300421A (en) 1994-06-30
JPH0748277A (ja) 1995-02-21
CA2103515A1 (en) 1994-02-11
CN1099798A (zh) 1995-03-08
AU4450093A (en) 1994-02-10
WO1994003589A3 (en) 1994-03-31
MX9304803A (es) 1994-05-31
HUT70982A (en) 1995-11-28
NO950483L (no) 1995-04-07
FI950567A (fi) 1995-04-05
EP0583142A3 (no) 1994-04-13
HU9500417D0 (en) 1995-04-28

Similar Documents

Publication Publication Date Title
NO976060D0 (no) Vaksiner mot hepatitt C
NO950483D0 (no) Vaksine mot hepatitt-A
DK0633784T3 (da) Hepatitisvacciner indeholdende 3-O-diacyleret monophosphoryl-lipid A
ATE209045T1 (de) Hepatitis b impfstoff
DE69332685D1 (de) Direktumsetzempfänger
FI930976A (fi) Mot tumoer riktande foerfarande och aemne
EP0533263A3 (en) A multivalent hepatitis b virus vaccine
ITMI921011A0 (it) Fionda a forcella
IL106609A0 (en) Hepatitis a virus vaccine
FI874276A0 (fi) Vaccin mot hepatitis a.
ITFE920013V0 (it) Endolancet a
BR7200437U (pt) Disposicao proporcionada a arandeia
KR930017660U (ko) 방 석
KR940005099U (ko) 방 석
ITMI920511A0 (it) Sedia a rotelle
FI394U1 (fi) Anslutning av en mellanvaegg mot undertaket
FI158U1 (fi) Skydd mot olyckor orsakade av armeringsjaern
BR7201288U (pt) Disposicao proporcionada a sematoro
FI281U1 (fi) I ett odlingsroer placerbar odlingskruka
ITMI910090U1 (it) Pannello a innesto
ITRM920005V0 (it) Mutadina a perdere
BR7001480U (pt) Disposicao proporcionada a bicicleta
ITLE910007A0 (it) P o v a r
BR7101923U (pt) Disposicao proporcionada a abaco
BR7100634U (pt) Disposicao proporcionada a techadura

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application